Research never stops

Archive



Jul 19, 2016

Evotec AG increases its profitability guidance for 2016

Hamburg, Germany, 19 July 2016: Evotec AG today announced that, in the context of the half year results published on 10 August 2016, it increases its financial guidance for the current year.

- read more
Jul 11, 2016

Evotec awarded contract from Antibiotic Research UK to begin integrated drug discovery collaboration

Hamburg, Germany, 11 July 2016: Evotec AG announced today a collaboration with Antibiotic Research UK to identify alternative means of treating infections that are resistant to currently available antibiotics.

- read more
Jul 06, 2016

Evotec enters license agreement for access to CRISPR-Cas9 gene editing technology

Hamburg, Germany, 06 July 2016: Evotec AG announced today that the Company has entered into a non-exclusive licence agreement with the Broad Institute of MIT and Harvard for the use of CRISPR-Cas9 gene editing technology.

- read more
Jun 29, 2016

Evotec and Ellersbrook join forces to accelerate TargetNASH

Hamburg, Germany, 29 June 2016: Evotec AG announced today that the investment company Ellersbrook GmbH & Co. KG, Germany, will invest into Evotec's internal TargetNASH programme.

- read more
Jun 14, 2016

Resolutions of the Annual General Meeting of Evotec AG

Hamburg, Germany, 14 June 2016: Evotec AG today announced that its shareholders approved all proposals the Company's Management put to vote at the Company's Annual General Meeting, which took place today, with the required majority.

- read more
Jun 10, 2016

Evotec receives European Mediscience Award for ‘Best Communication’

Hamburg, Germany, 10 June 2016: Evotec AG was awarded the European Mediscience Award for best communication.

- read more
May 24, 2016

Evotec extends integrated drug discovery alliance with Genentech

Hamburg, Germany, 24 May 2016: Evotec AG today announced that Genentech, a member of the Roche Group, has extended its integrated drug discovery alliance with Evotec for a further three years to discover novel small molecule therapeutics.

- read more
May 10, 2016

Evotec AG reports results of first quarter 2016

Hamburg, Germany, 10 May 2016: Evotec AG today reported financial results and corporate updates for the first quarter of 2016.

- read more
Apr 26, 2016

Evotec and ex scientia announce partnership to discover bispecific small molecule immuno-oncology therapeutics

Hamburg, Germany, Dundee, UK - 26 April 2016: Evotec AG and ex scientia Ltd (Dundee, UK) today announced a collaboration with the objective to discover and develop first-in-class bispecific small molecule immuno-oncology therapies.

- read more
Apr 19, 2016

Evotec and Pierre Fabre sign multi-year compound management agreement

Hamburg, Germany - 19 April 2016: Evotec AG today announced a multi-year compound management agreement with Pierre Fabre Laboratories, the 2nd largest private French pharmaceutical group.

- read more
Mar 22, 2016

Evotec FY 2015: Excellent execution meets first-in-class innovation

Hamburg, Germany - 22 March 2016: Evotec AG today announced its financial results for the fiscal year ended 31 December 2015.

- read more
Mar 22, 2016

Evotec spins off auto-immune disease company as 'Topas Therapeutics GmbH'

Hamburg, Germany - 22 March 2016: Evotec AG today announced the formation of a spin-off company in the field of nanoparticle-based therapeutics to treat immunological disorders.

- read more
Mar 10, 2016

Evotec achieves milestone in collaboration with Padlock Therapeutics

Feb 02, 2016

Evotec awarded grant from The Michael J. Fox Foundation for Parkinson's Research

Jan 12, 2016

Evotec achieves important milestone in TargetAD collaboration with Janssen in Alzheimer's disease

Jan 07, 2016

Evotec and UCB sign multi-year sample management agreement

Watch a short video clip on this press release

- read more